Apixaban CAS# 503612-47-3

pyridine-3-carboxaMide, Promotion Season Now in Store and Free Sample for Testing with Factory Price

• Chemical Name:pyridine-3-carboxaMide
• CAS No.:     503612-47-3
• Molecular Fomula:C25H25N5O4
• Molecular weight：459.5
• Appearance: white powder
• Sample：Available

Send Inquiry


Download Quotation

Description of pyridine-3-carboxaMide

pyridine-3-carboxaMide, sold under the tradename Eliquis, is an anticoagulant for the treatment of venous thromboembolic events. It is taken by mouth. It is a direct factor Xa inhibitor.
Apixaban was approved in Europe in 2012. It was approved in the U.S. in 2014 for treatment and secondary prophylaxis of deep vein thrombosis (DVT) and pulmonary embolism (PE). It is being developed in a joint venture by Pfizer and Bristol-Myers Squibb.

Basic Info of pyridine-3-carboxaMide

Basic Info
Numbering system
Properties
Basic Info

Numbering system

Properties

What is Apixaban?

• With the progress of science and technology and the development of society, chemical products have invariably permeated our daily lives, in medicine, food, cosmetics, electronics, industry, and other areas, becoming an essential part of our lives. One such product is Apixaban   which has developed particularly rapidly in recent years. Do you know aboutpyridine-3-carboxaMide?
• The official answer：Apixaban is a new oral factor Xa inhibitor co-developed by Bristol-Myers Squibb and Pfizer, under the trade name Eladol, is a new oral anticoagulant. On April 26, 2007, Bristol-Myers Squibb and Pfizer announced a collaboration to develop Apixaban, a new oral anticoagulant owned by Bristol-Myers Squibb, as an upgraded alternative to warfarin. Under the Chemicalbook collaboration agreement, Pfizer will pay Bristol-Myers Squibb an upfront payment of $250 million for 60% of the total development costs of the anticoagulant apixaban (effective January 1, 2007), while Bristol-Myers Squibb will cover the remaining 40%, thereby acquiring co-development and marketing rights for the drug. Iceland and Norway, are the first to be approved for the prevention of venous thrombosis in adult patients undergoing elective hip or knee replacement surgery.

What’s the application of Apixaban?

• Apixaban is an oral selective activation of factor X inhibitor that prevents thrombosis but has lower adverse effects of bleeding than the older drug warfarin and is used for thrombotic prophylaxis in patients who have undergone hip or knee replacement surgery. (1) Dual inhibitors of strong CYP3A4 and P-GP increase blood levels of apixaban: reduce ELIQUIS dose to 2.5 mg or avoid concomitant use.
• Concomitant use of strong CYP3A4 and P-GP inducers decreases blood levels of apixaban: avoid concomitant use.

Conclusion

Sincere to the customer and in good faith of quality is our forever followed motto. It’s the basement to be a human and do business. We take all responsibility for our products and service sincerely. We are a company integrating R&D, production, and sales. The design, research, and development of pharmaceutical intermediates including more than 330 kinds of pharmaceutical intermediates such as Anti-infectives, Cardiovascular and Cerebrovascular Systems, Digestive System, Santi-tumor, Nervous System, Geriatric Drugs, and Gynecological Drugs. At the same time, we have more than 4,000 factories in strategic cooperation with nearly 50,000 chemical products, so we can provide you with a one-stop purchasing service, which greatly saves customers’ procurement costs and time.

Keywords of Apixaban

pyridine-3-carboxaMide , 503612-47-3, buy  pyridine-3-carboxaMide, pyridine-3-carboxaMidesupplier, purchase  pyridine-3-carboxaMide,  pyridine-3-carboxaMide cost,  pyridine-3-carboxaMide manufacturer, order  pyridine-3-carboxaMide, high pur pyridine-3-carboxaMide  pyridine-3-carboxaMide

Hot Products